Amalgamated Financial’s Aura Biosciences AURA Stock Holding History

Amalgamated Financial’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$17K	Buy	+791	New	+$15.1K	﹤0.01%	2783

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Amalgamated Financial's AURA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Aura Biosciences (AURA) in Q1 2022: 791 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2783 among its holdings.

34 funds tracked by Wall St. Rank hold AURA as of Q1 2022.

Amalgamated Financial held 791 shares of Aura Biosciences worth $17K as of Q1 2022.
Aura Biosciences was a new Amalgamated Financial position in Q1 2022.
Aura Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2783 holding.
34 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.